[go: up one dir, main page]

CL2016000396A1 - Tratamiento contra el mieloma múltiple - Google Patents

Tratamiento contra el mieloma múltiple

Info

Publication number
CL2016000396A1
CL2016000396A1 CL2016000396A CL2016000396A CL2016000396A1 CL 2016000396 A1 CL2016000396 A1 CL 2016000396A1 CL 2016000396 A CL2016000396 A CL 2016000396A CL 2016000396 A CL2016000396 A CL 2016000396A CL 2016000396 A1 CL2016000396 A1 CL 2016000396A1
Authority
CL
Chile
Prior art keywords
multiple myeloma
against multiple
treatment against
treatment
tricotastin
Prior art date
Application number
CL2016000396A
Other languages
English (en)
Inventor
Polymeropoulos Mihael
William Licamele Louis
Lavedan Christian
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CL2016000396A1 publication Critical patent/CL2016000396A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/5751—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pistons, Piston Rings, And Cylinders (AREA)
  • Navigation (AREA)

Abstract

Tratamiento contra el mieloma múltiple que comprende la administración de tricotastina a (tsa)
CL2016000396A 2013-08-22 2016-02-22 Tratamiento contra el mieloma múltiple CL2016000396A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361869039P 2013-08-22 2013-08-22
US201361870747P 2013-08-27 2013-08-27

Publications (1)

Publication Number Publication Date
CL2016000396A1 true CL2016000396A1 (es) 2017-03-17

Family

ID=51492478

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2016000396A CL2016000396A1 (es) 2013-08-22 2016-02-22 Tratamiento contra el mieloma múltiple
CL2018001719A CL2018001719A1 (es) 2013-08-22 2018-06-22 Tratamiento contra el mieloma múltiple (divisional solicitud 201600396)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2018001719A CL2018001719A1 (es) 2013-08-22 2018-06-22 Tratamiento contra el mieloma múltiple (divisional solicitud 201600396)

Country Status (13)

Country Link
US (5) US20160199324A1 (es)
EP (2) EP3623011B1 (es)
JP (4) JP2016534115A (es)
KR (6) KR102465000B1 (es)
CN (2) CN105579100A (es)
AU (1) AU2014308704B2 (es)
BR (1) BR112016003609B1 (es)
CA (2) CA2921037C (es)
CL (2) CL2016000396A1 (es)
EA (1) EA037638B1 (es)
ES (2) ES2754199T3 (es)
MX (1) MX386151B (es)
WO (1) WO2015027125A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037667B1 (ru) 2013-08-22 2021-04-28 Ванда Фармасьютикалз Инк. Лечение рака
EA037638B1 (ru) * 2013-08-22 2021-04-23 Ванда Фармасьютикалз Инк. Лечение множественной миеломы
FI3651766T3 (fi) 2017-07-10 2024-11-18 Celgene Corp 4-(4-(4-(((2-(2,6-dioksopiperidin-3-yyli)-l-oksoisoindolin-4-yyli)oksi)metyyli)bentsyyli)piperatsin-1-yyli)-3-fluoribentsonitriili antiproliferatiivisena yhdisteenä
CN109913420A (zh) * 2019-03-07 2019-06-21 北京师范大学 Cdc20共表达基因网络作为胶质瘤治疗靶点的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218478A (en) 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
WO2002060430A1 (en) 2001-02-01 2002-08-08 Cornell Research Foundation, Inc. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
WO2005116259A2 (en) * 2004-05-21 2005-12-08 The Board Of Trustees Of The University Of Arkansas System Use of gene expression profiling to predict survival in cancer patient
GB0519405D0 (en) * 2005-09-23 2005-11-02 Univ Aberdeen Cancer therapy prognosis and target
WO2007067516A2 (en) * 2005-12-06 2007-06-14 Duke University Multiple myeloma
CN101495111A (zh) * 2006-05-26 2009-07-29 细胞基因公司 在联合治疗中使用免疫调节化合物的方法和组合物
US20110301055A1 (en) * 2008-12-05 2011-12-08 Nicholas James Dickens Methods for determining a prognosis in multiple myeloma
EA037667B1 (ru) * 2013-08-22 2021-04-28 Ванда Фармасьютикалз Инк. Лечение рака
EA037638B1 (ru) * 2013-08-22 2021-04-23 Ванда Фармасьютикалз Инк. Лечение множественной миеломы
DE102014117278A1 (de) 2014-11-25 2016-05-25 Krones Ag Hubeinheit zum Anheben und Absenken eines Behälters in einer Behälterbehandlungsanlage

Also Published As

Publication number Publication date
CL2018001719A1 (es) 2018-07-27
EA037638B1 (ru) 2021-04-23
JP2020073508A (ja) 2020-05-14
KR20220035275A (ko) 2022-03-21
US20160199324A1 (en) 2016-07-14
JP2023179435A (ja) 2023-12-19
MX386151B (es) 2025-03-18
EP3623011A1 (en) 2020-03-18
JP7698680B2 (ja) 2025-06-25
CN105579100A (zh) 2016-05-11
CA3171302A1 (en) 2015-02-26
KR102465000B1 (ko) 2022-11-09
CA2921037C (en) 2022-11-15
ES3018607T3 (es) 2025-05-16
KR20210021602A (ko) 2021-02-26
US20230346719A1 (en) 2023-11-02
EP3623011B1 (en) 2025-02-12
EP3036006A1 (en) 2016-06-29
NZ716669A (en) 2021-03-26
US20200009087A1 (en) 2020-01-09
CN113244205A (zh) 2021-08-13
KR102373721B1 (ko) 2022-03-11
KR20220153684A (ko) 2022-11-18
ES2754199T3 (es) 2020-04-16
US20180256521A1 (en) 2018-09-13
KR20160033780A (ko) 2016-03-28
KR20200011554A (ko) 2020-02-03
WO2015027125A1 (en) 2015-02-26
US20240342120A1 (en) 2024-10-17
AU2014308704A1 (en) 2016-02-25
US11737993B2 (en) 2023-08-29
CA2921037A1 (en) 2015-02-26
KR20170126019A (ko) 2017-11-15
JP2022017337A (ja) 2022-01-25
MX2016002308A (es) 2016-06-15
EA201690446A1 (ru) 2016-06-30
EP3036006B1 (en) 2019-10-09
AU2014308704B2 (en) 2019-10-10
BR112016003609B1 (pt) 2021-04-27
JP2016534115A (ja) 2016-11-04

Similar Documents

Publication Publication Date Title
BR112016006983A2 (pt) dispositivo para desinfecção de conectores de cateter
MY165759A (en) Pull-on diaper
ECSP17015977A (es) Terapia de combinacion
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
EP3017723A4 (en) Wearable chair device
CL2015002116A1 (es) Administración de compuesto anti-activin-a a un sujeto
BR112017018620A2 (pt) método de administração de tradipitanto, e, tradipitanto.
IN2014DE01038A (es)
BR112015023511A2 (pt) tensor
IN2013DE00266A (es)
CR20160448A (es) Nuevos derivados de piridina
PT3188599T (pt) Tratamentos médicos baseados em anamorelina
BR112015016577A2 (pt) elemento de fixação e seringa
AR097668A1 (es) Colorante-polímero
CL2016000396A1 (es) Tratamiento contra el mieloma múltiple
SG10201403043XA (en) Medical face masks
BR112015023782A2 (pt) conjunto de polias
BR112015018195A2 (pt) cateter de curvatura variável
BR112015024771A2 (pt) cateter
CL2015002666A1 (es) Formas de dosificación sólidas de antiemético de liberación prolongada
EP3271434C0 (de) Niedertemperatur-plasmabehandlung
GEP20217236B (en) Composition comprising pentose and polyphenolic compound
LT3233054T (lt) Pi3k/mtor inhibitoriaus vaisto formos, skirtos intraveniniam įvedimui
BR112015021575A2 (pt) composição fungicida
CL2016000171A1 (es) Formulación de metaxalona.